Generalized Pustular Psoriasis (GPP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Generalized Pustular Psoriasis Marketed and Pipeline Drugs Report Overview
By 2028, GlobalData estimates that the highest prevalence of GPP cases will be in South Korea and China. Generalized Pustular Psoriasis (GPP) is a subtype of psoriasis in which patients exhibit painful episodes of sterile pustules in their skin. Companies such as AbbVie and academic institutions both are investing heavily in the the clinical trials for GPP.
Key Mechanism of Action (Marketed) | · Receptor Agonist
· Biological Factor Inhibitor · Receptor Antagonist · Enzyme Inhibitor |
Key Routes of Administration (Marketed) | · Oral
· Topical · Injection |
Key Molecule Type (Marketed) | · Small Molecule
· Biologic |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Generalized Pustular Psoriasis Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for generalized pustular psoriasis.
The report also provides actionable insights on the clinical and commercial landscapes of generalized pustular psoriasis drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Key Mechanisms of Action (Pipeline) | · Receptor Antagonist
· Biological Factor Inhibitor |
Top Sponsors (Marketed and Pipeline Drugs) | · Abbvie
· Novartis · UCB · AstraZeneca · Bristol-Myers Squibb |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Generalized Pustular Psoriasis Marketed Drugs Segmentation by Mechanisms of Action
The key MoA in the marketed drugs for Generalized Pustular Psoriasis are receptor agonist, biological factor inhibitor, receptor antagonist, and enzyme inhibitor. The majority of marketed drugs used for GPP were receptor agonist in 2023, followed by biological factor inhibitor.
Generalized Pustular Psoriasis Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of men Generalized Pustular Psoriasis Marketed Drugs
Generalized Pustular Psoriasis Marketed Drugs Segmentation by Routes of Administration
The key RoA in GPP marketed drugs industry are oral, injection, and topical. Most of the Generalized Pustular Psoriasis marketed drugs were orally administered in 2023.
Generalized Pustular Psoriasis Marketed Drugs Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Generalized Pustular Psoriasis Marketed Drugs
Generalized Pustular Psoriasis Marketed Drugs Segmentation by Molecule Types
The key molecule types in the marketed drugs for Generalized Pustular Psoriasis are small molecule and biologic. The majority of marketed drugs for GPP were small molecules in 2023.
Generalized Pustular Psoriasis Marketed Drugs Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Generalized Pustular Psoriasis Marketed Drugs
Generalized Pustular Psoriasis Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA in the Pipeline drugs for Generalized Pustular Psoriasis are receptor antagonist and biological factor inhibitor. In 2023, receptor antagonist was the leading MoA for Generalized Pustular Psoriasis pipeline drugs.
Generalized Pustular Psoriasis Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy Full Report to Know More about the MoA of Generalized Pustular Psoriasis Pipeline Drugs
Generalized Pustular Psoriasis Marketed and Pipeline Drugs Market – Commercial Assessment
A few of the top sponsors in the Generalized Pustular Psoriasis marketed and pipeline drugs market are Abbvie, Novartis, UCB, AstraZeneca, and Bristol-Myers Squibb. In 2023, Abbvie conducted the highest number of completed trials, followed by Novartis.
Generalized Pustular Psoriasis Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the Generalized Pustular Psoriasis Marketed and Pipeline Drugs Market
Segments Covered in the Report
Generalized Pustular Psoriasis Marketed Drugs Mechanism of Action (Number of Drugs, 2023)
- Receptor Agonist
- Biological factor Inhibitor
- Receptor Antagonist
- Enzyme Inhibitor
Generalized Pustular Psoriasis Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Topical
Generalized Pustular Psoriasis Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Antagonist
- Biological factor Inhibitor
Generalized Pustular Psoriasis Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Suppository
- Injection
- Oral
- Inhalational
- Topical
Generalized Pustular Psoriasis Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
Scope
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Generalized Pustular Psoriasis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Generalized Pustular Psoriasis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for Generalized Pustular Psoriasis marketed drugs in 2023?
The majority of marketed drugs used for GPP were receptor agonist in 2023.
-
Which was the leading RoA for Generalized Pustular Psoriasis marketed drugs in 2023?
In 2023, most of the marketed drugs for Generalized Pustular Psoriasis were administered orally.
-
Which was the leading MoA for Generalized Pustular Psoriasis pipeline drugs in 2023?
In 2023, receptor antagonist was the leading MoA for Generalized Pustular Psoriasis pipeline drugs.
-
Who are the top sponsors for the Generalized Pustular Psoriasis marketed and pipeline drugs market?
A few of the top sponsors in the Generalized Pustular Psoriasis marketed and pipeline drugs market are Abbvie, Novartis, UCB, AstraZeneca, and Bristol-Myers Squibb among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.